Related Experiment Video
Updated: Jun 25, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Pediatric psoriasis: updates in biologic therapies
Smita V Sukhatme1, Alice B Gottlieb
1Department of Dermatology, Tufts Medical Center and Tufts University School of Medicine, 800 Washington Street, Boston, MA 02111, USA.
Dermatologic Therapy
|February 19, 2009
Summary
Pediatric psoriasis, especially moderate-to-severe cases, lacks FDA-approved systemic treatments. Tumor necrosis factor (TNF)-alpha inhibitors show promise, drawing from their success in other pediatric autoimmune diseases.
Area of Science:
- Pediatric dermatology
- Immunology
- Rheumatology
Background:
- Psoriasis affects children, necessitating early intervention to mitigate physical and psychological impacts.
- Moderate-to-severe pediatric psoriasis presents treatment challenges, with limited FDA-approved systemic options beyond topical corticosteroids.
- Adult treatments may carry higher risks for pediatric patients.
Purpose of the Study:
- To review current data on tumor necrosis factor (TNF)-alpha inhibitors for pediatric psoriasis.
- To examine the evidence supporting biologic approvals in other pediatric autoimmune conditions.
Main Methods:
- Literature review of studies on TNF inhibitors in pediatric psoriasis.
- Analysis of clinical trial data for biologics in pediatric autoimmune diseases.
Main Results:
- Advances in biologic therapies, particularly TNF-alpha inhibitors, offer new avenues for pediatric psoriasis treatment.
- Data from other pediatric autoimmune diseases inform the potential use and safety of biologics in psoriasis.
Conclusions:
- TNF-alpha inhibitors represent a significant therapeutic advance for moderate-to-severe pediatric psoriasis.
- Further research and clinical application of biologics are crucial for improving outcomes in young psoriasis patients.
Related Concept Videos
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...